OVO Biomanufacturing Ltd

OVO Biomanufacturing Ltd is a UK-based company specializing in innovative solutions for managing defective interfering particles in vaccine production, optimizing processes for both live attenuated and inactivated viral vaccines. Founded in 2019 in the United Kingdom, OVO Biomanufacturing Ltd focuses on providing software solutions for the biopharmaceutical sector. The company was founded by Phillip Gould, and it has engaged in one investment deal to date, with its most recent deal occurring on December 3, 2010. OVO Biomanufacturing specializes in innovative solutions for managing defective interfering particles (DIPs) in the vaccine production process.

Their core offering is a cloud-based software platform designed to optimize vaccine manufacturing by analyzing and controlling DIP populations during the production of both live attenuated and inactivated viral vaccines. This platform leverages Next Generation Sequencing (NGS) data to provide tailored recommendations on growth conditions, thereby enhancing the yield of immunogenic components. The technology is applicable across a broad range of viral vaccine manufacturers, including those operating in the USD 8 billion influenza vaccine market, and aims to serve both established and emerging entities in the biopharmaceutical sector. OVO's clients typically include vaccine manufacturers located in North America, Europe, and parts of Asia, where the demand for efficient and effective vaccine production solutions is critical in meeting public health needs.

OVO Biomanufacturing generates revenue through direct partnerships with vaccine manufacturers who utilize their software platform for optimizing production processes. The company engages in B2B transactions, offering licensing agreements or subscription-based models that enable clients to access and implement their technology over time. This structured approach allows clients to integrate OVO's solutions into their existing workflows, maximizing their production efficiency while remaining compliant with regulatory standards. The revenue model includes recurring fees associated with software updates and technical support, ensuring that manufacturers benefit from ongoing improvements in DIP management.

OVO's flagship platform is tailored for scalability, supporting a range of production volumes and conditions, which positions it favorably in the competitive landscape of vaccine manufacturing solutions. In December 2020, OVO Biomanufacturing Ltd raised venture funding from new investor Catapult Ventures Group, although financial terms have not been disclosed. The company plans to utilize this funding to enhance its software platform and expand its market reach, with a focus on penetrating additional regions in North America and Asia by 2022. OVO is also in the process of designing new product features that aim to further optimize vaccine production efficiency, targeting a launch by mid-2021.